Ken Fisher Sarepta Therapeutics, Inc. Transaction History

Fisher Asset Management, LLC

$229 Billion
Q2 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Fisher Asset Management, LLC holds 17,916 shares of SRPT stock, worth $2.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,916

Previous 18,021 0.58%

Holding current value

$2.2 Million

Previous $2.33 Million 21.36%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$113.33 - $163.85 $11,899 - $17,204	-105 Reduced 0.58%	17,916 $2.83 Million
Q1 2024 May 09, 2024	BUY	$93.7 - $141.53 $412,654 - $623,298	4,404 Added 32.34%	18,021 $2.33 Million
Q3 2023 Nov 13, 2023	SELL	$102.5 - $123.59 $369,307 - $445,294	-3,603 Reduced 20.92%	13,617 $1.65 Million
Q2 2023 Dec 12, 2023	BUY	$106.4 - $157.19 $383,359 - $566,355	3,603 Added 26.46%	17,220 $1.97 Million
Q2 2023 Aug 08, 2023	BUY	$106.4 - $157.19 $501,888 - $741,465	4,717 Added 37.73%	17,220 $1.97 Million
Q1 2023 Dec 12, 2023	BUY	$117.53 - $155.99 $76,159 - $101,081	648 Added 4.76%	14,265 $1.97 Million
Q1 2023 May 01, 2023	SELL	$117.53 - $155.99 $2,820 - $3,743	-24 Reduced 0.19%	12,503 $1.72 Million
Q4 2022 Feb 03, 2023	SELL	$100.86 - $132.13 $1.24 Million - $1.63 Million	-12,317 Reduced 49.58%	12,527 $1.62 Million
Q3 2022 Nov 08, 2022	SELL	$75.71 - $119.24 $299,963 - $472,428	-3,962 Reduced 13.75%	24,844 $2.75 Million
Q2 2022 Aug 09, 2022	SELL	$62.69 - $88.44 $169,012 - $238,434	-2,696 Reduced 8.56%	28,806 $2.16 Million
Q1 2022 May 05, 2022	SELL	$63.15 - $90.42 $4,925 - $7,052	-78 Reduced 0.25%	31,502 $2.46 Million
Q4 2021 Feb 02, 2022	BUY	$77.28 - $99.42 $10,664 - $13,719	138 Added 0.44%	31,580 $2.84 Million
Q3 2021 Oct 26, 2021	BUY	$65.97 - $92.48 $229,179 - $321,275	3,474 Added 12.42%	31,442 $2.91 Million
Q2 2021 Jul 27, 2021	SELL	$69.38 - $86.75 $34,828 - $43,548	-502 Reduced 1.76%	27,968 $2.17 Million
Q1 2021 Apr 27, 2021	BUY	$72.25 - $168.95 $19,290 - $45,109	267 Added 0.95%	28,470 $2.12 Million
Q4 2020 Jan 29, 2021	SELL	$125.56 - $178.74 $523,961 - $745,882	-4,173 Reduced 12.89%	28,203 $4.81 Million
Q3 2020 Nov 10, 2020	SELL	$127.12 - $172.34 $496,657 - $673,332	-3,907 Reduced 10.77%	32,376 $4.55 Million
Q2 2020 Aug 07, 2020	SELL	$93.0 - $171.7 $425,568 - $785,699	-4,576 Reduced 11.2%	36,283 $5.82 Million
Q1 2020 Apr 28, 2020	BUY	$82.38 - $131.64 $546,426 - $873,168	6,633 Added 19.38%	40,859 $4 Million
Q4 2019 Feb 12, 2020	SELL	$76.53 - $135.58 $146,554 - $259,635	-1,915 Reduced 5.3%	34,226 $4.42 Million
Q3 2019 Oct 29, 2019	BUY	$72.81 - $156.91 $50,457 - $108,738	693 Added 1.95%	36,141 $2.72 Million
Q2 2019 Jul 30, 2019	BUY	$112.21 - $151.95 $1.21 Million - $1.64 Million	10,788 Added 43.75%	35,448 $5.39 Million
Q1 2019 Apr 22, 2019	BUY	$106.67 - $151.68 $6,613 - $9,404	62 Added 0.25%	24,660 $2.94 Million
Q4 2018 Jan 25, 2019	BUY	$97.32 - $148.76 $12,943 - $19,785	133 Added 0.54%	24,598 $2.68 Million
Q3 2018 Oct 24, 2018	SELL	$115.31 - $161.51 $1.01 Million - $1.41 Million	-8,722 Reduced 26.28%	24,465 $3.95 Million
Q2 2018 Jul 09, 2018	SELL	$71.74 - $153.69 $433,596 - $928,902	-6,044 Reduced 15.41%	33,187 $4.39 Million
Q1 2018 May 11, 2018	SELL	$54.02 - $82.27 $983,164 - $1.5 Million	-18,200 Reduced 31.69%	39,231 $2.91 Million
Q1 2018 Apr 19, 2018	BUY	$54.02 - $82.27 $798,577 - $1.22 Million	14,783 Added 34.66%	57,431 $4.26 Million
Q4 2017 Jan 24, 2018	BUY	$47.64 - $56.75 $285 - $340	6 Added 0.01%	42,648 $2.37 Million
Q3 2017 Oct 17, 2017	BUY	$35.73 - $47.15 $1.52 Million - $2.01 Million	42,642	42,642 $1.93 Million

Others Institutions Holding SRPT

# of Institutions

556

Shares Held

85.6M

Call Options Held

3.67M

Put Options Held

1.75M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.8B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account